Anakinra Hepatotoxicity in a Patient With Adult-Onset Still's Disease

We report a 46-year-old white woman with adult-onset Still's disease (AOSD) treated with anakinra, a IL-1B receptor antagonist. Within weeks, her liver enzymes deteriorated; subsequent cessation and rechallenge confirmed anakinra-related drug-induced liver injury (DILI). Although AOSD has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Osman, Brahmania, Mayur, Alsahafi, Majid, Alkhowaiter, Saad, Erb, Sig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435404/
https://www.ncbi.nlm.nih.gov/pubmed/26157954
http://dx.doi.org/10.14309/crj.2015.45
Descripción
Sumario:We report a 46-year-old white woman with adult-onset Still's disease (AOSD) treated with anakinra, a IL-1B receptor antagonist. Within weeks, her liver enzymes deteriorated; subsequent cessation and rechallenge confirmed anakinra-related drug-induced liver injury (DILI). Although AOSD has been associated with liver involvement, little is known about the hepatotoxicity of anakinra. Heightened awareness by gastroenterologists and hepatologists is warranted.

Ejemplares similares